17.4 C
New York
Monday, September 20, 2021

EVOFEM Biosciences Inc. (EVFM) stock shows a decline. Why?


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


EVOFEM Biosciences Inc. (NASDAQ: EVFM), a commercial stage pharmaceutical company shows a downfall in its stock after the company reported its Q4 and full year 2020 results. The company aims to develop such products which can address the unfulfilled needs in women’s sexual and reproductive health.

EVOFEM Biosciences has launched its first commercial product Phexxi, which is made for prevention of pregnancy. It is the first and only hormone-free prescription vaginal get that has been approved in USA. Another of EVOFEM’s lead product is EVO100 which functions to prevent urogenital Chlamydia trachomatis and Neisseria gonorrhea infection in women.

What is happening?

EVOFEM Q4 results of 2020 are lower than what analysts had expected. The earning per share EPS of $0.50 misses by $0.14. Also, the revenue is recorded as $0.17M which was expected to be $1.52M.

 The loss in revenue was caused by heavy utilization of the Phexxi co-pay assistance program followed with fixed costs primarily associated with distributor fees on around 3300 shipments of Phexxi in the fourth quarter. This gross-to-net adjustment resulted in approximately $170,000 of net product sales.

As per the fourth quarter results of the company, it had $48.9M of unrestricted and $22.6M of restricted cash, the values were better in September-quarter results of the company with $86.7M unrestricted and $0.3M of restricted cash.

Now what?

The company has announced that the management will attend the upcoming H.C Wainwright Global life science conference in which they are going to explain about the commercialization of its new product, Phexxi (non-hormonal and should only be used when there is need to control child birth). The presentation will be available on March, 9.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.